| People | Locations | Statistics |
|---|---|---|
| Naji, M. |
| |
| Motta, Antonella |
| |
| Aletan, Dirar |
| |
| Mohamed, Tarek |
| |
| Ertürk, Emre |
| |
| Taccardi, Nicola |
| |
| Kononenko, Denys |
| |
| Petrov, R. H. | Madrid |
|
| Alshaaer, Mazen | Brussels |
|
| Bih, L. |
| |
| Casati, R. |
| |
| Muller, Hermance |
| |
| Kočí, Jan | Prague |
|
| Šuljagić, Marija |
| |
| Kalteremidou, Kalliopi-Artemi | Brussels |
|
| Azam, Siraj |
| |
| Ospanova, Alyiya |
| |
| Blanpain, Bart |
| |
| Ali, M. A. |
| |
| Popa, V. |
| |
| Rančić, M. |
| |
| Ollier, Nadège |
| |
| Azevedo, Nuno Monteiro |
| |
| Landes, Michael |
| |
| Rignanese, Gian-Marco |
|
Malcolm, Karl
Queen's University Belfast
in Cooperation with on an Cooperation-Score of 37%
Topics
Publications (21/21 displayed)
- 2023A multipurpose ‘CZL’ vaginal ring for non-hormonal contraception and STI/HIV prevention
- 2021Custom silicone elastomers for improved mechanical performance and reduced hormone binding in a dapivirine/levonorgestrel vaginal ring
- 2021Preliminary formulation development of silicone elastomer vaginal rings for sustained release of metronidazole, sucrose and lactobacillus
- 2021Formulation development of an ethylene vinyl acetate ring for sustained release of the experimental entry inhibitor DS003
- 2021Silicone elastomer formulations for improved performance of a multipurpose vaginal ring releasing dapivirine and levonorgestrelcitations
- 2019Dapivirine-releasing vaginal rings produced by plastic freeforming additive manufacturingcitations
- 2019Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTEScitations
- 2019Post-use ring weight, residual drug content and drug depletion zone thickness as objective measures of user adherence to a contraceptive progesterone vaginal ringcitations
- 2019Towards a dapivirine and levonorgestrel multipurpose vaginal ring: Investigations into the reaction between levonorgestrel and addition-cure silicone elastomerscitations
- 2019Mechanical testing methods for drug-releasing vaginal ringscitations
- 2019In vitro release testing methods for drug-releasing vaginal ringscitations
- 2018Density Mediated Drug Release From Dapivirine Vaginal Rings Produced by Additive Manufacturing
- 2017Packing polymorphism of dapivirine and its impact on the performance of a dapivirine-releasing silicone elastomer vaginal ringcitations
- 2014Thermal properties and eutectic behaviour of dapivirine in combination with steroid hormones and other antiretrovirals
- 2011Dual functional ionic liquids as plasticisers and antimicrobial agents for medical polymerscitations
- 2010Development of liposome-based freeze-dried rods for vaginal vaccine delivery against HIV-1citations
- 2009Persistence of antimicrobial activity through sustained release of triclosan from pegylated silicone elastomerscitations
- 2009Development and evaluation of a vaginal ring device for sustained delivery of HIV microbicides to non-human primate
- 2008The Effect of Tacticity on the Conformational Properties of Poly(1-olefin sulfone)scitations
- 2004Controlled release of a model antibacterial drug from a novel self-lubricating silicone biomaterialcitations
- 2001Determination of the drug solubility at the melt temperature in silicone intravaginal rings using dynamic mechanical analysis
Places of action
| Organizations | Location | People |
|---|
article
In vitro release testing methods for drug-releasing vaginal rings
Abstract
Drug-releasing vaginal rings are torus-shaped devices, generally fabricated from thermoplastics or silicone elastomers, used to administer pharmaceutical drugs to the human vagina for periods typically ranging from three weeks to twelve months. One of the most important product performance tests for vaginal rings is the in vitro release test. Although it has been fifty years since the a vaginal ring device was first described in the scientific literature, and despite seven drug-releasing vaginal rings having been approved for market, there is no universally accepted method for testing in vitro drug release, and only one non-compendial shaking incubator method (for the estradiol-releasing ring Estring®) is described in the US Food and Drug Administration's Dissolution Methods Database. Here, for the first time, we critically review the diverse range of test methods that have been described in the scientific literature for testing in vitro release of drug-releasing vaginal rings. Issues around in vitro-in vivo correlation and modelling of in vitro release data are also discussed.